The difference between insulinotropic agents and sensitizers is different in definition, mechanism of action, and applicable population. 1. Definition: insulin secretagogues mainly promote insulin secretion of drugs, applicable to patients whose pancreatic islet function still exists, the representative drugs are sulfonylureas and glargine drugs; insulin sensitizer, mainly to increase the body’s sensitivity to insulin, the representative drugs are glargine drugs. 2. Mechanism of action: insulin secretion promoter, mainly to promote insulin secretion, while inhibiting the secretion of glucagon, has a dual role; insulin sensitizer, is to increase insulin sensitivity, so that the insulin effect can be fully played, to promote the lowering of blood glucose. 3. Applicable people: insulin sensitizers are generally applicable to patients with type 2 diabetes whose pancreatic B-cell function still exists and whose blood glucose level cannot be well controlled by diet and exercise; while sensitizers are mainly applicable to patients who cannot achieve the effect of other hypoglycemic drugs and insulin treatment, and they are the initial first-line drugs for patients with type 2 diabetes. Insulin stimulants and sensitizers should be used under the guidance of a specialist to avoid discomfort and delay in treatment.